Home › Trial NCT06008106
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
- Trial IDNCT06008106
- StatusRecruiting
- PhasePhase 3
- Study typeInterventional
- SponsorShanghai Kechow Pharma, Inc.
- Enrollment165
- Start date2023-11-02
- ConditionsMelanoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.